FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma
Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Mar 17, 2010
Trial Information
Current as of June 06, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II)
- • histological verification will be obtained either by microsurgery or by stereotactic biopsy
- • patients older than 18 years
- • Karnofsky Performance Score \>=70
- • pregnant or nursing female patients will not be included in this study
- Exclusion Criteria:
- • patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills
- • patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan
- • medical history of a metastatic brain disease
- • patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.
About Ludwig Maximilians University Of Munich
Ludwig-Maximilians-University of Munich (LMU Munich) is a prestigious research institution in Germany, renowned for its commitment to advancing medical science and improving patient care through innovative clinical research. As a leading sponsor of clinical trials, LMU Munich leverages its extensive academic resources and interdisciplinary expertise to conduct rigorous studies aimed at evaluating new therapeutic interventions and advancing healthcare knowledge. The university fosters collaboration among researchers, clinicians, and healthcare professionals, ensuring that trials are designed and executed with the highest ethical standards and scientific integrity. Through its dedication to excellence in research, LMU Munich aims to contribute significantly to the development of effective treatments and enhance the overall health outcomes for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, Bavaria, Germany
Duesseldorf, North Rhine Westphalia, Germany
Patients applied
Trial Officials
Joerg C. Tonn, Prof. Dr.
Principal Investigator
Department of Neurosurgery, LMU Munich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials